麻疹-风疹疫苗双腔注射装置:三国引入不同尺寸装置的潜在影响
本研究利用HERMES免疫供应链模型,在贝宁、印度比哈尔邦和莫桑比克将常规10剂次麻疹-风疹冻干疫苗替换为单剂次双腔注射装置,评估不同每剂体积(5.2–26 cm3)和每剂价格(0.70、1.40美元)对疫苗可及性、开瓶浪费和总成本的影响。结果显示,每剂体积5.2 cm3时疫苗可及性与基线相似且开瓶浪费减少;体积增大至7.5–26 cm3时可及性降低1%–14%;仅贝宁和莫桑比克在5.2 cm3、0.70美元/剂且总接种剂次变化<1%时总成本改善。结论认为单剂次双腔装置体积需不大于5.2 cm3才不致显著影响其他疫苗流通。
要点
- 每剂体积5.2 cm3时疫苗可及性与基线相似,开瓶浪费减少。
- 体积7.5–26 cm3时疫苗可及性降低1%–14%,主要因冷链和运输利用率上升。
- 仅贝宁和莫桑比克在5.2 cm3、0.70美元/剂且接种剂次变化<1%时总成本改善。
核心结论
- 在3个不同国家的供应链中,单剂次麻疹-风疹双腔注射装置体积需不大于5.2 cm3才不致显著影响其他疫苗流通。
研究设计与样本
- 使用HERMES生成的贝宁、印度比哈尔邦和莫桑比克免疫供应链模型,将常规10剂次麻疹-风疹冻干疫苗替换为单剂次双腔注射装置,每剂体积范围5.2–26 cm3,每剂价格0.70或1.40美元。
主要发现
- 每剂体积5.2 cm3时,双腔注射装置在中等受限供应链中疫苗可及性与基线相似,开瓶浪费减少,每剂接种总成本与基线相似。
- 每剂体积7.5–26 cm3时,因冷链储存利用率增加1%–7%、平均峰值运输利用率增加2%–44%,疫苗可及性降低1%–14%。
- 每剂体积26 cm3时,疫苗可及性降低9%–14%。
- 每剂接种总成本在各情景间变化不一,因疫苗采购成本下降与接种剂次减少相伴随。
- 仅贝宁和莫桑比克在每剂体积5.2 cm3、每剂价格0.70美元且总接种剂次较基线变化<1%时,引入双腔注射装置使每剂接种总成本改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: By pairing diluent with vaccines, dual-chamber vaccine injection devices simplify the process of reconstituting vaccines before administration and thus decrease associated open vial wastage and adverse events. However, since these devices are larger than current vaccine vials for lyophilized vaccines, manufacturers need guidance as to how the size of these devices may affect vaccine distribution and delivery. METHODS: Using HERMES-generated immunization supply chain models of Benin, Bihar (India), and Mozambique, we replace the routine 10-dose measles-rubella (MR) lyophilized vaccine with single-dose MR dual-chamber injection devices, ranging the volume-per-dose (5.2-26 cm3) and price-per-dose ($0.70, $1.40). RESULTS: At a volume-per-dose of 5.2 cm3, a dual-chamber injection device results in similar vaccine availability, decreased open vial wastage (OVW), and similar total cost per dose administered as compared to baseline in moderately constrained supply chains. Between volumes of 7.5 cm3 and 26 cm3, these devices lead to a reduction in vaccine availability between 1% and 14% due to increases in cold chain storage utilization between 1% and 7% and increases in average peak transport utilization between 2% and 44%. At the highest volume-per-dose, 26 cm3, vaccine availability decreases between 9% and 14%. The total costs per dose administered varied between each scenario, as decreases in vaccine procurement costs were coupled with decreases in doses administered. However, introduction of a dual-chamber injection device only resulted in improved total cost per dose administered for Benin and Mozambique (at 5.2 cm3 and $0.70-per-dose) when the total number of doses administered changed <1% from baseline. CONCLUSION: In 3 different country supply chains, a single-dose MR dual-chamber injection device would need to be no larger than 5.2 cm3 to not significantly impair the flow of other vaccines.
引用
- Wedlock PT, Mitgang EA, Siegmund SS, et al. Dual-chamber injection device for measles-rubella vaccine: The potential impact of introducing varying sizes of the devices in 3 countries. Vaccine. 2018. PMID: 30146404. doi:10.1016/j.vaccine.2018.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。